Site-Dependence Scalp Cooling System to Prevent Hair Loss during Chemotherapy
نویسندگان
چکیده
منابع مشابه
Prevention of chemotherapy-induced hair loss by scalp cooling.
BACKGROUND Chemotherapy-induced temporary hair loss is one of the most common and distressing side-effects of cancer therapy. Scalp cooling to reduce this hair loss is a controversial issue for many doctors and nurses. This may be due to inadequate knowledge. METHODS This review from 53 publications and three personal communications focuses on the efficacy of the treatment, side-effects, poss...
متن کاملNumerical Simulation of Scalp Cooling to Prevent Chemotherapy–Induced Alopecia
One way of treating cancer is by chemotherapy. Side–effects of chemotherapy include hair loss. Cooling the scalp during treatment can reduce hair loss. For this cooling, a cap containing a cold fluid (cold cap) is used. However, the rate of success of this method varies strongly, because precise mechanisms of preservation are unknown. Temperature and perfusion are thought to play an important r...
متن کاملScalp lesions and hair loss.
17-year-old white male complained of scalp problems for the preceding 8 months. Initially he developed a painful lesion, which looked like a blood blister, on the right posterior crown. It was believed to be a wrestling injury and was treated with topical antiseptics. This patient was an expert wrestler and competed frequently. At some point his tinea pedis (athlete’s foot) was treated with ter...
متن کاملScalp metastases and scalp cooling for chemotherapy-induced alopecia prevention.
Alopecia is one of the most common adverse events of chemotherapy and although it is not life threatening it can be psychologically devastating. In an effort to reduce chemotherapy-induced hair loss various preventive measurements, such as the scalp cooling technique, tourniquet and medications, have been developed since 1970 [1]. Methods that have been applied in order to induce scalp hypother...
متن کاملReducing chemotherapy-induced alopecia with scalp cooling.
JL The frequency of alopecia varies with different chemotherapy regimens. According to data from Ralph M. Trüeb, MD, alopecia occurs in more than 80% of patients receiving antimicrotubule agents (eg, paclitaxel [Taxol, Bristol-Myers Squibb]), 60–100% of patients receiving topoisomerase inhibitors (eg, doxorubicin), more than 60% of patients receiving alkylators (eg, cyclophosphamide), and 10–50...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Bioengineering & Biomedical Science
سال: 2015
ISSN: 2155-9538
DOI: 10.4172/2155-9538.1000158